FDA OKs Durvalumab in Limited-Stage SCLC

News
Article

Results from the phase 3 ADRIATIC trial led to the approval of durvalumab in limited-stage SCLC.

Results from the phase 3 ADRIATIC trial led to the approval of durvalumab in limited-stage SCLC.

Results from the phase 3 ADRIATIC trial led to the approval of durvalumab in limited-stage SCLC.

The FDA has approved durvalumab (Imfinzi) for patients with limited-stage small cell lung cancer who have not progressed after concurrent platinum-based chemotherapy and radiation therapy, according to a press release from the agency.1

Results from the phase 3 ADRIATIC trial (NCT03703297) led to the approval.2 A total of 730 patients were enrolled and randomly assigned 1:1:1 to either durvalumab monotherapy, durvalumab in combination with tremelimumab (Imjudo), or placebo.

Durvalumab was given at 1500 mg every 4 weeks if patients weighed 30 kg or more and 20 mg/kg every 4 weeks for those who weighed less than 30 kg.

Topline data included an overall survival (OS) of 55.9 months (95% CI, 37.3-not reached) in the monotherapy arm, and 33.4 months (95% CI, 25.5-39.9) in the placebo arm. Additionally, there was a significant progression-free survival (PFS) improvement compared with the placebo arm (HR, 0.76; 95% CI, 0.61-0.95; P = .0161).

The median PFS was 16.6 months (95% CI, 10.2-28.2) in the monotherapy arm and 9.2 months (95% CI, 7.4-12.9) in the placebo arm.

The most common adverse effects included pneumonitis or radiation pneumonitis and fatigue.

References

  1. FDA approves durvalumab for limited-stage small cell lung cancer. News release. FDA. December 4, 2024. Accessed December 4, 2024. https://shorturl.at/0eID1
  2. Senan S, Spigel D, Cho BC, et al. Durvalumab as consolidation therapy in limited-stage SCLC (LS-SCLC): outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial. Presented at the 2024 European Society for Medical Oncology Congress (ESMO); September 13-17, 2024; Barcelona, Spain. LBA81.
Recent Videos
Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
CAR T-cell therapies or other agents that impact the immune system in the long term may be important to keep in mind for the management of SCLC.
Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.
In the SWOG S2409 PRISM trial, over 800 patients with small cell lung cancer will receive different treatment regimens based on their disease subtype.
Related Content
Those who had elevated ProGRP at baseline and normalized ProGRP following chemoradiotherapy achieved a median PFS of 49.3 months vs 7.8 months in those who had persistently elevated ProGRP.

Progastrin-Releasing Peptide Levels Correlate With OS and PFS in LS-SCLC

Tim Cortese
October 4th 2025
Article

Those with limited-stage small cell lung cancer who had elevated ProGRP levels at baseline had worse OS and PFS outcomes vs those with normalized levels.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.

FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC

Russ Conroy
October 2nd 2025
Article

Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Considering Dosing and AE Management Strategies With Tarlatamab in SCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
March 24th 2025
Podcast

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.

Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC

Roman Fabbricatore
September 30th 2025
Article

Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.

The frontline treatment algorithm in SCLC is poised to look “radically different” in the upcoming years, according to Anne Chiang, MD, PhD.

Understanding “Paradigm-Changing” Events in Small Cell Lung Cancer Care

Russ Conroy
September 25th 2025
Article

The frontline treatment algorithm in SCLC is poised to look “radically different” in the upcoming years, according to Anne Chiang, MD, PhD.